CGM for Management of Type 2 Diabetes in Pregnancy
NCT: NCT06628453 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications? Participants will: 1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis
Frequently Asked Questions
What is CGM for Management of Type 2 Diabetes in Pregnancy?
CGM for Management of Type 2 Diabetes in Pregnancy is a clinical trial registered under NCT06628453. Current status: RECRUITING.
What is the status of NCT06628453?
The current status of NCT06628453 (CGM for Management of Type 2 Diabetes in Pregnancy) is: RECRUITING.
When did CGM for Management of Type 2 Diabetes in Pregnancy start?
CGM for Management of Type 2 Diabetes in Pregnancy started on 2025-04-08.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.